ZENTARIS Canadian Trademark Information

On Thursday, April 26, 2001, a canadian trademark registration was filed for ZENTARIS by AETERNA ZENTARIS INC. *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1101127. The current status of this trademark filing is Interruption of proceeding. The ZENTARIS trademark is filed in the description of Chemical used in industry and science namely peptides, molecules, enzymes substrates, natural extracts, reactives, solvents, metals, metalloids; pharmaceutical preparations used for the treatment of cancer, pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer, pharmaceutical preparations used for the treatment of urological diseases, pharmaceutical preparations used for the treatment of hormonal disorders, peptides-containing pharmaceutical preparations used for hormonal and tumors treatments, pharmaceutical preparations used for the treatment of endocrine diseases, pharmaceutical preparations used for the treatment of carcinoid tumors, pharmaceutical preparations used for the treatment of hematological diseases, pharmaceutical preparations used for the treatment of age-related diseases namely diabetes, cardiovascular diseases, age-related macular degeneration (AMD), dementia, pharmaceutical preparations used for the treatment of ophtalmological disorders, pharmaceutical preparations used for the treatment of reproductive system disorders, pharmaceutical preparations used for the treatment of endometriosis, pharmaceutical preparations used for the treatment of uterine myoma, pharmaceutical preparations used for the treatment of non-malignant tumors, pharmaceutical preparations used for the treatment for benign prostatic hyperplasia (BPH), pharmaceutical preparations used for the treatment of tropical diseases related to parasite or virus, pharmaceutical preparations used for the treatment of infectious disease for specific problematic bacteria namely M. tuberculosis, B. anthracis, H. pylori, C. difficile and nosocomial diseases, pharmaceutical preparations used for the treatment of leishmaniasis, pharmaceutical preparations used for the treatment of obesity, pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes, pharmaceutical preparations containing cytotoxic products (conjugated or not) in the form of pills or injectable, pharmaceutical preparations used as a tubulin inhibitor, pharmaceutical preparations based on LHRH antagonists platform, pharmaceutical preparations based on bombesin antagonist platform, pharmaceutical preparations based on inhibitors of the Akt pathway, pharmaceutical preparations based on angiogenesis inhibitors platform, pharmaceutical preparations used to induce apoptosis, pharmaceutical preparations used to stimulate growth hormone secretagogue (GHS). , Scientific and industrial research. , Chemical used in industry and science namely peptides, molecules, enzymes substrates, natural extracts, reactives, solvents, metals, metalloids; pharmaceutical preparations used for the treatment of cancer, pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer, pharmaceutical preparations used for the treatment of urological diseases, pharmaceutical preparations used for the treatment of hormonal disorders, peptides-containing pharmaceutical preparations used for hormonal and tumors treatments, pharmaceutical preparations used for the treatment of endocrine diseases, pharmaceutical preparations used for the treatment of carcinoid tumors, pharmaceutical preparations used for the treatment of hematological diseases, pharmaceutical preparations used for the treatment of age-related diseases namely diabetes, cardiovascular diseases, age-related macular degeneration (AMD), dementia, pharmaceutical preparations used for the treatment of ophtalmological disorders, pharmaceutical preparations used for the treatment of reproductive system disorders, pharmaceutical preparations used for the treatment of endometriosis, pharmaceutical preparations used for the treatment of uterine myoma, pharmaceutical preparations used for the treatment of non-malignant tumors, pharmaceutical preparations used for the treatment for benign prostatic hyperplasia (BPH), pharmaceutical preparations used for the treatment of tropical diseases related to parasite or virus, pharmaceutical preparations used for the treatment of infectious disease for specific problematic bacteria namely M. tuberculosis, B. anthracis, H. pylori, C. difficile and nosocomial diseases, pharmaceutical preparations used for the treatment of leishmaniasis, pharmaceutical preparations used for the treatment of obesity, pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes, pharmaceutical preparations containing cytotoxic products (conjugated or not) in the form of pills or injectable, pharmaceutical preparations used as a tubulin inhibitor, pharmaceutical preparations based on LHRH antagonists platform, pharmaceutical preparations based on bombesin antagonist platform, pharmaceutical preparations based on inhibitors of the Akt pathway, pharmaceutical preparations based on angiogenesis inhibitors platform, pharmaceutical preparations used to induce apoptosis, pharmaceutical preparations used to stimulate growth hormone secretagogue (GHS). , Scientific and industrial research. .